CN-122005578-A - Use of caffeol palmitate, GPX4 binding formulation and PML inhibitor

Abstract

The embodiment of the application discloses application of caffeol palmitate, a GPX4 combined preparation and a PML inhibitor, and can expand the application of caffeol palmitate.

Inventors

• LI YIFANG
• WANG YUAN
• ZHONG JIANGMING
• HE RONGRONG
• SHU PENG
• OUYANG SHUHUA
• JIANG SHAN

Assignees

• 深圳护家科技(集团)股份有限公司

Dates

Publication Date

20260512

Application Date

20260324

Priority Date

20250925

Claims (13)

1. 1. Use of caffeol palmitate for the preparation of a GPX4 binding formulation.
2. 2. The use according to claim 1, a GPX4 binding formulation for activating GPX4 activity.
3. 3. The use according to claim 1, a GPX4 binding formulation for inhibiting PML protein expression.
4. 4. The use according to claim 1, the GPX4 binding formulation is for inhibiting the formation of PML nucleosomes.
5. 5. Use of caffeol palmitate for the preparation of a GPX4 activity-activating formulation.
6. 6. Use of caffeol palmitate in the preparation of a PML inhibitor.
7. 7. The use according to claim 6, wherein the PML inhibitor is for inhibiting PML protein expression, and/or inhibiting PML nucleosome formation, and/or inhibiting cellular senescence.
8. 8. Use of caffeol palmitate for the preparation of an inhibitor of cellular senescence.
9. A gpx4 binding formulation comprising cafestol palmitate.
10. A pml inhibitor comprising cafestol palmitate.
11. 11. Use of caffeol palmitate for the preparation of a GPX4 agonist.
12. 12. Use of cafestol palmitate in the preparation of an anti-ageing formulation or a skin care formulation.
13. 13. Use of caffeol palmitate for the preparation of a lipid ROS inhibitor, SA- β -Gal inhibitor, matrix metalloproteinase 3 inhibitor, matrix metalloproteinase 1 inhibitor, interleukin 6 inhibitor, P53 phosphorylation inhibitor, or P21 inhibitor.

Description

Use of caffeol palmitate, GPX4 binding formulation and PML inhibitor Technical Field The invention relates to the technical field of application of caffeol palmitate, in particular to application of caffeol palmitate, a GPX4 binding preparation and a PML inhibitor. The application claims priority, the application number of the prior application (Chinese application patent application) is 2025113792632, the application of the caffeol palmitate, the GPX4 combined preparation and the PML inhibitor are named, and the priority date is 2025, 09 and 25. Background Caffeol palmitate (Cafestol Palmitate, CP for short) is an active substance derived from coffee beans, and has a chemical structural formula shown in figure 1, and CAS number 81760-46-5. It has now been found that cafestol palmitate is mainly useful for the treatment of diabetes (see patent document EP3148525B 1), for enhancing lipid barrier synthesis (see patent document US6716437B 1). But in addition, cafestol palmitate is still less useful. For example, there are few reports on how to use cafestol palmitate for the modulation of glutathione peroxidase 4 (Glutathione Peroxidase, GPX 4) or promyelocytic leukemia protein (Promyelocytic leukemia, PML). Thus, in general, there is less research in the prior art on cafestol palmitate. Disclosure of Invention It is an aim of embodiments of the present application to address at least one of the above-mentioned problems with the background and to provide corresponding advantages. It is another object of embodiments of the present application to provide a use of caffeol palmitate, a GPX4 binding formulation and an inhibitor, which can expand the new applications of caffeol palmitate. The embodiment of the application mainly realizes the aim through the following technical scheme. In a first aspect, embodiments of the present application provide the use of caffeol palmitate in the preparation of a GPX4 binding formulation. It should be noted that the number of the substrates, GPX4 refers to glutathione peroxidase 4. In some embodiments, a GPX4 binding formulation is used to activate GPX4 activity according to the use of the first aspect. In some embodiments, a GPX4 binding formulation is used to inhibit PML protein expression according to the use of the first aspect. In some embodiments, a GPX4 binding formulation is used to inhibit PML nucleosome formation according to the use of the first aspect. In a second aspect, embodiments of the present application provide a use of CP in the preparation of a GPX4 activity-activating formulation. In a third aspect, embodiments of the present application provide a use of CP in the preparation of a PML inhibitor. In some embodiments, according to the use of the third aspect, the PML inhibitor is for inhibiting PML protein expression, In some embodiments, according to the use of the third aspect, the PML inhibitor is for inhibiting the formation of PML nucleosomes. In some embodiments, according to the use of the third aspect, the PML inhibitor is for inhibiting cell senescence. In a fourth aspect, embodiments of the present application provide a use of CP in the preparation of a cell senescence inhibitor. In some technical solutions, CP is used to: Activating the enzymatic activity of GPX 4; Inhibiting RSL 3-induced increase in expression of PML protein; inhibiting RSL 3-induced lipid ROS production; inhibition of RSL 3-induced increased expression of SA- β -Gal; Inhibiting RSL 3-induced expression of a gene associated with the SASP senescence-associated secretion phenotype, the gene associated selected from any of matrix metalloproteinase 3 (matrix metalloproteinase, mmp 3), matrix metalloproteinase 1 (matrix metalloproteinase, mmp 1), and interleukin 6 (interleukin-6, il-6); Inhibition of activation of the P53-P21 signaling pathway, in particular, inhibition of RSL 3-induced P53 phosphorylation, and inhibition of RSL 3-induced increase in P21 expression. It is understood that CP has an effect of inhibiting cell senescence, and thus can be used for preparing an anti-aging preparation. In some embodiments, CP can be used to inhibit aging of skin cells to protect the skin, and thus can be used to prepare skin care formulations. The skin cells are HEK293 cells or HDFs cells. In a fifth aspect, embodiments of the present application provide a GPX4 binding formulation comprising CP. In a sixth aspect, embodiments of the present application provide an inhibitor, comprising CP. The beneficial effects of the embodiment of the invention include: In some embodiments, embodiments of the present application provide for the use of CP in the preparation of GPX4 binding formulations. Specifically, there is a binding effect of CP to GPX4, and GPX4 binding agents can bind to GPX4 through CP. In some embodiments, embodiments of the application also provide for the use of a CP in the preparation of a GPX4 activity-activating formulation. The CP has obvious activating effect on the enzyme acti